US opens temporary path for peptide compounding

The United States health department said on Wednesday that licensed pharmacies and physicians may temporarily compound a set of unapproved peptides while regulators decide whether to permit their use on a permanent basis, a move that opens a regulated route for peptide compounding without granting approval to any of the products involved. The interim policy, published in the Federal Register, covers BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax. According to Reuters, the department will not take enforcement action against compounders who meet conditions on ingredient quality, manufacturing standards, safety reporting, labelling and patient-specific prescriptions.

Compounded drugs are not approved by the Food and Drug Administration, which means the agency does not review their safety, effectiveness or quality before they reach patients. The department said the policy does not constitute approval of the peptides or of the compounded medicines made from them. It also said the policy may be reconsidered if safety signals or product-quality problems emerge. The notice was filed on Wednesday and is scheduled for publication on Friday, with a comment period running for a fortnight after publication, according to a second report on the Federal Register filing.

Peptides are short chains of amino acids, the building blocks of proteins. Some peptide-based medicines have established medical uses, while the compounds named in the interim policy have been promoted online for purposes ranging from tissue repair to sleep and pain relief. Their popularity has grown sharply over the past year, driven in part by endorsements from wellness influencers, and several have been sold as research-use-only products by foreign manufacturers. The department said steering patients away from that unregulated supply was part of its reasoning, because products sold outside established pharmaceutical oversight can pose a safety risk when their contents and manufacturing standards are unknown.

What the interim policy allows

The policy applies to state-licensed pharmacies, federal facilities and licensed physicians who compound under section 503A of the drug law. That section sets conditions under which a compounded drug can be exempt from approval, from the usual directions-for-use labelling rule and from full manufacturing-practice requirements. One condition is that the bulk ingredient sits on a list built by the secretary through regulation. The department said the list covering these compounds is still in rulemaking, and the interim policy bridges the gap until a final rule either adds a compound to that list or keeps it off.

The non-enforcement position is limited in scope. Each product must contain only a single listed compound, and it must be made for a named patient on a prescription. The original manufacturer must be registered with the Food and Drug Administration, in compliance with manufacturing practice and named on a certificate of analysis, while any repacker must have checked that manufacturer. Compounders must report the products they make and must report serious adverse events to the MedWatch programme and to the relevant states, whether or not the event is judged to be related to the drug. Labels must carry the words "This is a compounded drug product. Not for resale." Routes vary by compound, and an oral form needs documentation, kept by the compounder, showing that the formulation reaches adequate absorption in people. Where a device is packaged with a product, the only device allowed is a cleared syringe.

The six compounds are promoted for different purposes. The tissue-repair pair are often taken together in a combination popularly known as the "Wolverine stack". The others are described in reporting on the policy as treatments for insomnia, wound healing and inflammatory conditions, obesity and osteoporosis, and migraines and chronic pain. Those descriptions reflect how the compounds are promoted, not findings by regulators that they are safe or effective for those uses. Agency scientists have concluded that available evidence is insufficient to establish their safety and effectiveness, according to reporting on the filing.

Why the decision is contested

The decision follows a recommendation from a Food and Drug Administration advisory committee in July to allow the compounds in compounding. Reuters reported that several panel members had ties to peptide-selling businesses or clinics, while the department said all cleared standard ethics checks. That background matters because the committee vote was advisory only and did not itself authorise use. The interim policy now gives pharmacies a defined, temporary basis to operate while the formal rulemaking continues, rather than leaving the question to enforcement discretion on a case-by-case basis.

Supporters in the peptide field welcomed the move. Lee Rosebush, chair of the American Academy of Peptide Medicine, described the policy as a "landmark regulatory milestone" and said it cleared the path for clinical innovation and wider access. Jeff Cohen, co-founder of the American Peptide Association, warned that the policy could amplify tension between federal and state regulators, adding that states may not follow the federal move to relax the rules. That warning points to a practical limit on the policy: compounding is also governed at state level, and a federal decision not to enforce does not by itself settle how every state regulator will treat the same products.

Health Secretary Robert F. Kennedy Jr. has publicly supported broader access to peptides, calling himself a "big fan" of the treatments in past remarks reported by Reuters. The department framed the policy as part of a broader effort to confront risks from black-market products, with a spokesperson saying the administration was working to put prevention and patient safety at the centre of health care. Telehealth companies have also been watching the decision closely. Hims & Hers Health has been preparing to roll out peptide offerings once cleared by federal regulators, according to Reuters, and analysts estimate the peptide industry could quickly become a market worth two billion to three billion dollars if legitimised.

For patients, the distinction at the heart of the policy is easy to miss and important to keep clear. A compounded medicine made under the interim policy is not an approved drug, and the temporary pause on enforcement is not a finding that a product works or that it is safe for a particular person. Anyone considering such a product still needs a prescription, and the product should come from a licensed pharmacy or physician working within the conditions set out in the policy. The next step is the formal rulemaking process, which could place some, all or none of the compounds on the permanent list. Until that rule is final, the interim policy stands as a conditional pause, not a settled answer. Readers can read the original reporting in the Reuters report and further detail on the filing in the Federal Register analysis.